Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVT-1075 + MVT-5873 in CA19-9 positive malignancies
NCT03118349Phase 1Terminated
- Sponsor
- BioNTech SE
- Start
- Jun 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVT-1075 in pancreatic ductal adenocarcinoma (PDAC) and malignant neoplasm, sponsored by BioNTech SE. Primary endpoints: Maximum Tolerated Dose at 1 year and Occurrence of graded adverse events at 1 year. Started Jun 2017; status: terminated.
02
Drugs
MVT-1075
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)malignant neoplasm
Beyond the preview
Go deeper on NCT03118349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118349.